Drugs Submission Guide

Source: Drugs author guidelines.

Use this page when deciding:

• whether the proposed Review has clinical-prescribing relevance

• whether the author team has sustained authority in the clinical-pharmacology subfield

• whether topic timing is right

• a clear clinical-prescribing-relevant synthesis

• author authority with primary-research and clinical-pharmacology experience

• topic-timing case

• direct contribution to clinical pharmacology

• a 1-2 page outline with author authority statement

• Topic recently covered in Drugs.

• Author standing in basic pharmacology rather than clinical pharmacology.

• Scope framed as basic-science synthesis rather than clinical-prescribing-relevant Review.

• Clinical-prescribing relevance is peripheral.

Drugs is among the highest-impact clinical-pharmacology journals.

Clinical-prescribing focus: the journal differentiates from Pharmacological Reviews (basic-pharmacology focus) and Clinical Pharmacology and Therapeutics (broader scope) by demanding direct clinical-prescribing relevance.

Authority expectation: editors weigh clinical-pharmacology authority and clinical experience.

The strongest Drugs inquiry letters establish:

• the clinical-prescribing-relevant synthesis in one sentence

• the author authority with clinical-pharmacology record

• the topic-timing case

• the practice relevance

Drugs publishes no stage-by-stage timetable; the journal page reports a median of 8 days from submission to first decision, with no year printed beside it. The guidelines describe the editorial procedure as internal review by editorial staff, external peer review, and copy editing. The journal editor performs an initial appraisal of each manuscript, and unsuitable submissions may be assessed for suitability for other Adis journals by appropriate editors.

Internal review by editorial staff

The journal editor performs an initial appraisal of each manuscript. If the paper was peer reviewed by another journal as part of a prior submission, the editor also assesses the previous editorial and referee comments and how they were dealt with.

Editor scope and clinical-relevance screen

Drugs' editor filter prioritizes clinical aspects of drug treatment with strong links to clinical practice. The most common desk reject in our review work: preclinical mechanism-of-action studies without clinical-application framing, pure-pharmacology papers without prescribing-decision relevance, and basic discovery work that should have gone to Drug Discovery Today or a discovery-focused journal. A manuscript considered unsuitable for Drugs may be assessed for suitability for other Adis journals, but it will not be progressed to external peer review for an alternative journal without the author's permission.

External peer review

Peer reviewer identities are kept confidential, but author identities are known to the reviewers. Reviewers are asked to disclose potential conflicts of interest, and the final decision on acceptability for publication lies with the journal editor.

Decision, revision, and production

The majority of manuscripts require some degree of revision following peer review before they can be accepted. All accepted manuscripts are copy edited, and authors receive proofs for approval. Open-access option available through Springer Open Choice with APC at acceptance.

• the synthesis is clinical-prescribing relevant

• the author team has clinical-pharmacology authority

• the topic-timing case is strong

• practice relevance is direct

• Is Drugs journal a good journal?

Before contacting, run your proposal through a Drugs journal presubmission readiness check.

Follow the published mechanics, then judge the submission from the other side of the desk. The review tells you whether your paper clears the Drugs fit check before upload, especially around topic proposal that collides with recent Drugs coverage, author authority that is scientific but not clinical-prescribing credible, and inquiry framed as basic pharmacology rather than a prescribing decision. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across Manusights submission reviews for Review proposals targeting Drugs, three patterns generate the most consistent inquiry declines. They are visible in the inquiry letter, outline, clinical question, author-authority paragraph, reference map, and proposed figures or tables before a full manuscript exists.

Topic proposal that collides with recent Drugs coverage

For Drugs proposals, the most common avoidable problem is topic timing. The inquiry letter proposes a Review on a drug class, indication, mechanism, or treatment strategy that Drugs or a close Adis title has already covered recently. The outline may be competent, the authors may be credible, and the references may be current, but the proposal does not explain why readers need this Review now. The manuscript components that reveal the risk are the title, outline headings, recent-reference map, proposed tables, and author-authority statement.

The stronger inquiry begins with a timing argument. It should identify the clinical-prescribing decision that has changed since the last major Review, such as new trial data, updated safety signals, guideline movement, comparative-effectiveness questions, real-world evidence, label changes, or unresolved sequencing decisions. The outline should not look like a general encyclopedia entry. It should show how the Review will help clinicians choose, monitor, combine, avoid, or sequence therapies.

If the proposal cannot distinguish itself from recent Drugs, Clinical Pharmacokinetics, CNS Drugs, Targeted Oncology, Pharmacological Reviews, or Clinical Pharmacology & Therapeutics coverage, the timing case is weak.

A Drugs presubmission readiness check can identify whether the inquiry letter, outline, references, and proposed tables make the timing case clear enough before you contact the journal.

Check topic proposal that collides with recent drugs coverage before submitting to Drugs →

Author authority that is scientific but not clinical-prescribing credible

Drugs is not simply a high-impact pharmacology venue. In our pre-submission review work, proposals often fail because the author team has strong laboratory, molecular, or pharmacology credentials but insufficient evidence of clinical-prescribing authority for the exact topic. The CV may show publications, but the inquiry letter does not show that the team can synthesize comparative efficacy, safety, dosing, monitoring, populations, contraindications, or guideline-relevant decision points. That gap is especially visible in the author-authority paragraph and the proposed table list.

The stronger proposal makes authority specific. It names the authors' sustained work in the drug class, disease area, clinical pharmacology problem, systematic-review evidence base, guideline space, or prescribing population. If the lead authors are basic scientists, the package should include a clinical co-author who understands treatment decisions. If the proposal covers a rapidly changing therapeutic area, the reference map should show command of recent trials, regulatory changes, and safety discussions.

If the paper is a narrative Review, the outline still needs a transparent logic for source selection and interpretation.

This is where adjacent routing matters. Pharmacological Reviews may be better for mechanism-heavy synthesis. Clinical Pharmacology & Therapeutics may be better for translational clinical pharmacology and policy-facing work. CNS Drugs, Targeted Oncology, or BioDrugs may own topic-specific audiences. Drugs is strongest when the Review helps clinicians and clinical pharmacologists interpret drug therapy in practice.

Check author authority that is scientific but not clinical prescribing credible before submitting to Drugs →

Inquiry framed as basic pharmacology rather than a prescribing decision

The third failure mode is a mismatch between the scientific content and the editorial promise. We see proposals whose outline begins with molecular pharmacology, receptor biology, preclinical models, or mechanism-of-action history, then adds clinical relevance at the end. That structure can work for a basic-pharmacology Review, but it is risky for Drugs when the title, abstract-style summary, proposed figures, and cover letter do not foreground a clinical-prescribing question.

The stronger inquiry reverses the order. It starts with a clinician-facing problem: which patients benefit, which risk groups need monitoring, how therapies compare, when to switch, how safety changes use, or where evidence remains uncertain. Mechanism belongs in the outline only where it clarifies clinical action. The proposed tables should be decision tools: comparative trials, approved indications, safety warnings, drug interactions, population-specific dosing, monitoring considerations, or treatment sequencing. The cover letter should say what decision the Review will improve.

If the proposal cannot be rewritten around a prescribing decision, a basic pharmacology, translational medicine, or specialty therapeutic journal may be a more honest target. Drugs submissions are strongest when the inquiry letter, outline, author team, and reference map all show clinical-pharmacology judgment.

Check your Drugs proposal against clinical prescribing substance before submission →

This page was researched from Drugs journal's author guidelines, Adis editorial-policy materials, Clarivate JCR data, and our pre-submission review work on presubmission inquiries.

Source limitations: Springer Nature publishes the current submission-guideline page, journal scope, editorial policies, and article-type framework. It does not publish invitation-planning notes or proposal-level decline reasons. Manusights observations are anonymized pre-submission review patterns and are included only as practical author guidance.

After the official guidance, the practical screen is the set of failure patterns we see when the inquiry letter, outline, clinical question, author-authority statement, reference map, and cover letter do not support a clinical-prescribing Review.

For the underlying journal profile, see Drugs.